Oragenics (OGEN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OGEN Oragenics

Watchlist

1.0600
+0.0500+4.95%

Trading Jul 26 12:18 ET

5.92MMarket Cap-125P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Oragenics Shares Are Trading Higher After the Company Announced It Developed a New Formulation for Its Novel Neurosteroid
BenzingaJul 10 14:40 ET
Express News | Oragenics Develops New Formulation For Lead Drug Candidate ONP-002 For Concussion; Plans Phase II Study To Assess Safety, Feasibility, And Effectiveness Through Blood Biomarker Profiles And Functional Outcomes
BenzingaJul 10 08:06 ET
Express News | Oragenics: Improves Intranasal Drug Formulation for Treating Concussed Patients
ReutersJul 10 08:03 ET
Express News | Oragenics Develops Automated Intranasal Device Prototype For Treating Concussed Patients
BenzingaJun 27 08:31 ET
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
OragenicsJun 27 00:00 ET
Oragenics, Inc. Announces Closing of Public Offering
OragenicsJun 26 00:00 ET

Comments

Jaguar8

Jun 27 07:31

NEWS

$Oragenics(OGEN.US)$
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics (NYSE American: OGEN) has announced the development of an automated intranasal device for treating concussed patients. The new prototype is designed for initial use in acute settings where patients are confused, dazed, or unconscious. Oragenics' lead drug candidate, ONP-002, aims to target the brain through nasal delivery. A Phase II study will evaluate ONP-002's effectiveness on blo...

Jaguar8

Jun 26 15:48

NEWS

$Oragenics(OGEN.US)$
Oragenics, Inc. Announces Closing of Public Offering
Oragenics announced the closing of its public offering of 1,100,000 shares at $1.00 per share, raising approximately $1.1 million. The funds will support the development of their ONP-002 product candidate and cover general corporate expenses. Dawson James Securities acted as the sole placement agent, and the offering was made under a shelf registration statement filed with the SEC. Legal representation was provided by ...

Jaguar8

Jun 24 17:45

NEWS

$Oragenics(OGEN.US)$
Oragenics, Inc. Announces Proposed Public Offering
Oragenics, Inc. (NYSE: OGEN), a company focused on intranasal pharmaceuticals for neurological disorders, announced a proposed public offering of its common stock or pre-funded warrants.
All securities in the offering will be sold by Oragenics. The proceeds will fund the development of its ONP-002 product candidate and cover general corporate expenses. Dawson James Securities, Inc. will serve as the sole placement agen...